Antimicrobial guidance update
This article was originally published in The Gray Sheet
Executive Summary
Final guidance in FDA's pipeline on 510(k) submissions for devices or combination products that incorporate antimicrobial agents faces delays from a change in reviewers at the Office of Chief Council followed by the change in administration, the agency says (1"The Gray Sheet" Sept. 1, 2008, p. 6). Once finalized, FDA will begin new guidance on performance testing for the devices. "The majority of antimicrobials that we see on medical devices do elute off the device to a greater or lesser extent," said Sheila Murphey, infection control branch chief at FDA's device center. "We need to know how much; we need to know how much over a period of time; we need to know how much over a long period of time." Performance testing should be quantitative and support indications and conditions for use. It may include in vitro, in vivo and clinical testing, Murphey said
You may also be interested in...
FDA Finalizing Guidance For Devices Containing Antimicrobial Agents
Revisions to a draft guidance on 510(k) submissions for devices or combination products that incorporate antimicrobial agents are awaiting final sign-off at FDA, an agency staffer said last week
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.